Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 9;16(12):1193–1200. doi: 10.1080/15384101.2017.1320005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Taylor & Francis

PMC Copyright notice

Figure 4. — Synergy assessment of palbociclib in combination with a variety of chemotherapeutic agents in CRC cell lines under hypoxia. HT-29, RKO and HCT-116 CRC cell lines were treated with the indicated concentrations of palbociclib in combination with CPT11 (A and B), 5-FU (C) or Oxaliplatin (D) for 48 hours in various non-constant ratios/doses. (A) Representative fluorescent images of palbociclib in combination with CPT11 in a panel of 3 CRC cell lines are shown. Combination index (CI) <1, = 1 and >1 respectively indicate synergism, additivity or antagonism. CI < 0.5 indicates very strong synergy. Red colored numbers highlight synergy at the indicated concentrations.